文献速递心脑血管急症消化、代谢与肾脏急症

高剂量三价与标准剂量四价流感疫苗对高危心血管病患者死亡或心肺住院的影响:一项随机临床试验

Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01
一句话结论高危心血管病患者中,高剂量三价流感疫苗较标准剂量四价疫苗未显著降低全因死亡或心肺住院(HR 1.06,95%CI 0.97-1.17),流感疫苗接种仍强烈推荐。

该实用性多中心双盲活性对照随机试验纳入5260例近期急性心梗或心衰住院且至少1项额外危险因素的高危心血管病患者,随机接受高剂量三价或标准剂量四价灭活流感疫苗,最多接种3个流感季。主要终点为全因死亡或心肺住院复合终点。高剂量组疫苗相关不良反应更常见(40.5% vs 34.4%),严重不良反应2.1% vs 1.7%。

要点

  • 高剂量组疫苗相关不良反应发生率40.5%,高于标准剂量组34.4%;严重不良反应分别为2.1%和1.7%。
  • 该人群近期有急性心梗或心衰住院且至少1项额外危险因素,平均年龄65.5岁,72%为男性,63%有心衰。
  • 研究覆盖3个流感季,共157个中心,5260例参与者,99.4%完成试验。
  • 流感疫苗接种在该人群中仍强烈推荐,不应因本试验结果而改变接种推荐。

适用人群与场景

  • 近期发生急性心肌梗死或心力衰竭住院、且至少具有1项额外危险因素的高危心血管病患者。
  • 研究场景为美国与加拿大157个中心的门诊/社区疫苗接种,非急诊或ICU床旁接种场景。
  • 平均年龄65.5岁(SD 12.6),72%为男性,63%有心力衰竭。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:实用性多中心双盲活性对照随机临床试验,157个中心,5260例参与者,随机分为高剂量三价组(n=2630)和标准剂量四价组(n=2630),最多接种3个流感季。
  • 疫苗相关不良反应:高剂量组1449例(40.5%) vs 标准剂量组1229例(34.4%);严重不良反应55例(2.1%) vs 44例(1.7%)。
  • 99.4%(5226例)参与者完成试验,共接种7154剂次疫苗。

证据类型、等级与局限

  • 证据类型:随机临床试验(RCT),实用性多中心双盲活性对照设计。
  • 原文未给出正式证据等级或推荐强度分级。
  • 局限性:原文未明确列出;设计上为活性对照而非安慰剂对照,未报告流感发病率作为终点。

对床旁实践的改变

  • 本试验结果不支持在高危心血管病患者中常规优先选用高剂量三价流感疫苗以降低死亡或心肺住院风险;标准剂量四价疫苗仍为合理选择。
  • 高剂量三价疫苗不良反应更常见(40.5% vs 34.4%),接种时需告知患者。
  • 流感疫苗接种在该人群中仍强烈推荐,不应因本试验阴性结果而延迟或放弃接种。
  • 适用人群为近期急性心梗或心衰住院且至少1项额外危险因素者;不适用于其他人群的疫苗选择决策。

指南或共识出处

  • 原文未提及指南或共识名称;试验注册号ClinicalTrials.gov NCT02787044。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Influenza is temporally associated with cardiopulmonary morbidity and mortality among those with cardiovascular disease who may mount a less vigorous immune response to vaccination. Higher influenza vaccine dose has been associated with reduced risk of influenza illness.

OBJECTIVE: To evaluate whether high-dose trivalent influenza vaccine compared with standard-dose quadrivalent influenza vaccine would reduce all-cause death or cardiopulmonary hospitalization in high-risk patients with cardiovascular disease.

DESIGN, SETTING, AND PARTICIPANTS: Pragmatic multicenter, double-blind, active comparator randomized clinical trial conducted in 5260 participants vaccinated for up to 3 influenza seasons in 157 sites in the US and Canada between September 21, 2016, and January 31, 2019. Patients with a recent acute myocardial infarction or heart failure hospitalization and at least 1 additional risk factor were eligible.

INTERVENTIONS: Participants were randomly assigned to receive high-dose trivalent (n = 2630) or standard-dose quadrivalent (n = 2630) inactivated influenza vaccine and could be revaccinated for up to 3 seasons.

MAIN OUTCOMES AND MEASURES: The primary outcome was the time to the composite of all-cause death or cardiopulmonary hospitalization during each enrolling season. The final date of follow-up was July 31, 2019. Vaccine-related adverse events were also assessed.

RESULTS: Among 5260 randomized participants (mean [SD] age, 65.5 [12.6] years; 3787 [72%] men; 3289 [63%] with heart failure) over 3 influenza seasons, there were 7154 total vaccinations administered and 5226 (99.4%) participants completed the trial. In the high-dose trivalent vaccine group, there were 975 primary outcome events (883 hospitalizations for cardiovascular or pulmonary causes and 92 deaths from any cause) among 884 participants during 3577 participant-seasons (event rate, 45 per 100 patient-years), whereas in the standard-dose quadrivalent vaccine group, there were 924 primary outcome events (846 hospitalizations for cardiovascular or pulmonary causes and 78 deaths from any cause) among 837 participants during 3577 participant-seasons (event rate, 42 per 100 patient-years) (hazard ratio, 1.06 [95% CI, 0.97-1.17]; P = .21). In the high-dose vs standard-dose groups, vaccine-related adverse reactions occurred in 1449 (40.5%) vs 1229 (34.4%) participants and severe adverse reactions occurred in 55 (2.1%) vs 44 (1.7%) participants.

CONCLUSIONS AND RELEVANCE: In patients with high-risk cardiovascular disease, high-dose trivalent inactivated influenza vaccine, compared with standard-dose quadrivalent inactivated influenza vaccine, did not significantly reduce all-cause mortality or cardiopulmonary hospitalizations. Influenza vaccination remains strongly recommended in this population.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02787044.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Vardeny O, Kim K, Udell JA, et al. Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial. JAMA. 2021. PMID: 33275134. doi:10.1001/jama.2020.23649

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。